The Enforcement Premium in Healthcare Assets

The Enforcement Premium in Healthcare Assets.

Splitbox Journal • Market Brief

For the long-term capital allocator, regulatory enforcement is not a hurdle but a floor for asset valuation.

Nairametrics reported that the National Agency for Food and Drug Administration and Control (NAFDAC) has blacklisted Onifam Laboratories Ltd, its CEO, and directors from the Nigerian pharmaceutical market. This follows investigations into regulatory misrepresentation and the circumvention of established processes. When enforcement agencies move beyond fines to full blacklisting, they alter the risk-adjusted returns of the entire sector.

We view this institutional hardening as a signal that the cost of regulatory arbitrage is rising. In the Lagos trade corridor, where compliance creates a legitimate barrier to entry, these actions protect the terminal value of compliant operators. They ensure that market pricing is determined by product quality and transparency rather than the temporary gains of substandard operations.

While enforcement actions can create friction in local supply chains, they are necessary for the maturation of the private healthcare market in Nigeria. A credible regulatory floor reduces the indemnity risk for institutional investors looking to underwrite pharmaceutical manufacturing.

Disciplined capital seeks markets where the rules are predictable and the consequences for violation are absolute. Protecting the integrity of the regulatory system is the only way to ensure the long-term compounding of legitimate business value.

More investment perspectives: splitboxltd.com

— Splitbox Journal